POLBF (Poolbeg Pharma) Accumulated Depreciation : $0.00 Mil (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Poolbeg Pharma Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Poolbeg Pharma Accumulated Depreciation Historical Data

The historical data trend for Poolbeg Pharma's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma Accumulated Depreciation Chart

Poolbeg Pharma Annual Data

Trend

Dec21

Dec22

Dec23

Accumulated Depreciation

Poolbeg Pharma Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Accumulated Depreciation	Get a 7-Day Free Trial			-	-	-	-	-

Poolbeg Pharma Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Poolbeg Pharma Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Poolbeg Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (OTCPK:POLBF) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

POLB:UK 7JN:Germany

Address

42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX

Website

https://www.poolbegpharma.com

Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.